Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects

Angiology

Volumn 57, Issue 2, 2006, Pages 211-218

  Marketou, Mary E ^a   Zacharis, Evangelos A ^a   Nikitovic, Dragana ^a   Ganotakis, Emmanuel S ^a   Parthenakis, Frangiskos I ^a   Maliaraki, Niki ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXIDE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HEPTANOIC ACID DERIVATIVE; LIPID PEROXIDE; PYRROLE DERIVATIVE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART SCINTISCANNING; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; AGED; BLOOD; FOLLOW UP; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645751479     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970605700212     Document Type: Article

References (29)

1. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876-1890, 2001.
2. Ridker PM, Hennekens CH, Roitman-Johnson B, et al: Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 351:88-92, 1998.
3. Ridker PM, Rifai N, Pfeffer M, et al: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101:2149-2153, 2000.
4. Case CC, Ballantyne CM: Statins and inflammatory markers. Curr Atheroscler Rep 4:42-47, 2002.
5. Ascer E, Bertolami MC, Venturinelli ML, et al: Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177:161-166, 2004.
6. Rezaie-Majd A, Maca T, Bucek R, et al: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22:1194-1199, 2002.
7. Schartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 285:1711-1718, 2001.
8. Tsiara S, Elisaf M, Mikhailidis DP: Early vascular benefits of statin therapy. Curr Med Res Opin 19:540-556, 2003.
9. Laufs U, Wassmann S, Hilgers S, et al: Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88:1306-1307, 2001.
10. John S, Delles C, Jacobi J, et al: Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 37:1351-1358, 2001.
11. Plenge JK, Hernandez TL, Weil KM, et al: Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-1452, 2002.
12. Wassmann S, Faul A, Hennen B, et al: Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 93:e98-e103, 2003.
13. Tamai O, Matsuoka H, Itabe H, et al: Single LDL-aphaeresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 95:76-82, 1997.
14. Mellwig KP, Baller D, Gleichmann U, et al: Improvement of coronary vasodilation capacity through single LDL aphaeresis. Atherosclerosis 139:173-178, 1998.
15. Thome SA, Abbot SE, Winyard PG, et al: Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells. Heart 75:11-16, 1996.
16. Chen LY, Nichols WW, Hendricks J, et al: Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis. Am Heart J 129:211-218, 1995.
17. Yamamoto A, Hoshi K, Ichihara K: Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 361:143-149, 1998.
18. Pritchard KA, Groszek L, Smalley DM, et al: Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 77:510-518, 1995.
19. Murphy RT, Foley JB, Mulvihill N, et al: Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 87:446-448, 2001.
20. Detmar M, Tenorio S, Hettmannsperger U, et al: Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 98:147-153, 1992.
21. Watson C, Whittaker S, Smith N, et al: IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol 105:112-119, 1996.
22. Schmidt AM, Hori O, Chen JX, et al: Advanced glycation end-products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995.
23. Yamashita H, Shimada K, Seki E, et al: Concentrations of interleukins, interferon and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 91:133-166, 2003.
24. Buffon A, Biasucci LM, Liuzzo G, et al: Widespread coronary inflammation in unstable angina. N Engl J Med 347:5-12, 2002.
25. Foody JM, Nissen SE: Effectiveness of statins in acute coronary syndromes. Am J Cardiol 88:31F-35F, 2001.
26. Weissberg P: Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. Atherosclerosis 147(suppl 1):S3-S10, 1999.
27. Hojo Y, Ikeda U, Katsuki T, et al: Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 84:83-87, 2004.
28. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 109(23 suppl 1):III39-43, 2004.
29. Fehr T, Kahlert C, Fierz W, et al: Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175:83-90, 2004.